TRIGR Therapeutics, a US-based Biopharmaceutical company, and ABL Bio Corporation, a South Korean biotechnology company, jointly announced today that it had entered into a binding agreement for TRIGR to license the global commercial rights to ABL Bio’s pipeline of novel therapeutic antibodies to treat cancer.
AstraZeneca has divested seven drugs from its anaesthetics portfolio through a $770m deal with Aspen Global Incorporated (AGI).nThe UK firm continues its spree of selling off unwanted assets, with this latest agreement conferring global commercialisation rights to AGI for the next ten years, spanning key markets such as Australia, Brazil, China and Japan.
One of the more eyebrow-raising names for some in the biopharma industry is said to be billionaire Dr. Patrick Soon-Shiong, CEO of I-O biotech NantKwest and a former surgeon, who is believed to be the highest paid CEO of 2015 (nearly $150 million), despite his company being very early stage.